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Abbreviation   Full Name 
PPAR   Peroxisome proliferator-activated receptors  
OEA   N-oleoylethanolamine 
NAAA   N-acylethanolamine-hydrolyzing acid amidase 
FAAH   Fatty acid amide hydrolase 
NAE   N-acylethanolamines 
OEA   N-oleoylethanolamine 
PEA   Palmitoylethanolamine 
SEA   N-stearoylethanolamine 
AEA   Anandamide 
PBS   Phosphate buffered solution 
1H-NMR   1H Nuclear magnetic resonance  
13C-NMR   13C Nuclear magnetic resonance  
δ   Chemical shift 
d   Doublet 
dd   Doublet of doublet 
q   Quartet 
s   Singlet 
t   Triplet 
m   Multiplet 
TC   Total cholestrol 



















化物酶体增殖活化受体 PPAR-α ( Peroxisome Proliferator-Activated Receptors )而
产生降低食欲，促进脂质代谢，调节脂质平衡，调节能量代谢的生理活性。这一
重要生理活性使 OEA 成为降血脂药物的新型先导化合物，然而，OEA 作为内源









① 本论文设计合成了 36 种化合物，并利用 MS、1H-NMR, 13C-NMR 对化
合物进行了结构鉴定；利用熔点和 LC-MS 对化合物的纯度进行了鉴定。 
② 将 36 种化合物分别利用小鼠急性高血脂模型，以总胆固醇、总甘油三酯
为指标进行降血脂活性筛选，结果表明，多数化合物均有较好的降血脂活性，尤
其以化合物 N31 和 N16，降低血清总甘油三酯分别为 81.06 %、83.66 %；降低血
清中总胆固醇分别为 72.09 %、77.49 %。 
③ 将已获得的 36 种化合物进行体外酶活实验检测，结果表明 36 种化合物
均有较好的抑酶活性，化合物 N9 和 N16 的酶抑制活性尤其明显。化合物 N9 和
N16 在体外 100μM 对 FAAH 酶的抑制率分别为 98.35 %和 84.90 %； 对 NAAA
酶的抑制率分别为 80.82%和 95.58 %。其中，化合物 N9、N16 对 FAAH 的抑制
的 IC50 分别为 22.48 μM  和 22.56 μM；对 NAAA 的抑制，IC50 分别为 18.55 μM


















系数 q2 分别为 0.447 和 0.505，相关系数 r2分别为 0.974 和 0.968, 标准偏差 SEE


























Oleoylethanolamide (OEA), an endogenous unsaturated fatty acid ethanolamide, 
can inhibit food intake, promote lipolysis, regulate lipid metabolism and energy 
expenditure by activating peroxisome proliferator-activated receptorsα(PPAR-α). 
These bioactivities of OEA make it a new lead compound with hypolipidemic 
activity. However, OEA is easy to be hydrolyzed by fatty acid amide hydrolase 
(FAAH) and N-acylethanolamine-hydrolyzing acid amidase,(NAAA), and lose its 
activity. So design and screening of some compounds which can activate PPAR-αas 
well as resist the hydrolysis of NAAA and FAAH are of meaning and important for 
the development of new-type hypolipidemic agents. 
The structure of OEA has obvious features including three parts : hydrophilic 
head, linker and hydrophobic tail. Every of these three parts can be modified. In order 
to get extensively structure- activity relationship, we divide the lead compound into  
three parts (i.e.A, B and C) reasonably, provide several alternative function groups for 
every part, assembly different function groups from part A, B and C into 36 molecules 
according to the structure of reported PPAR-α agonists.  
① In this article, we have synthesized 36 compounds. The structures of the 
synthesized new compounds have been identified by mass spectrum, 1H-NMR, 
13C-NMR and melting points. 
② The hypolipidemic activity of the synthesized compounds was evaluated by 
Triton WR-1339-induced hyperlipidemic mice as an experimental model. Most of the 
tested compounds significantly reduced the levels of total cholesterol (TC) and total 
triglycerides (TG) in the plasma at 100mg/Kg oral dose. It is noteworthy that N9 and 
N16 exhibit superior hypolipidemic activity to OEA, while the other compounds have 
equal or less hypolipidemic activity. More surprisingly is the result obtained with 
“N31 and N16”, which can reduce plasma TC and TG by 81.06 % and 83.66 % ，
72.09 % and 94.70 % respectively. Under the same condition, fenofibrate can lower 
the plasma TC and TG by 74.3 % and 91.35 %. It is mean that N31 and N16 are 
slightly more efficient than fenofibrate which is known as a good hypolipidemic agent 


















③ In a separate series of experiments, all 36 compounds were assessed for their 
ability to inhibit FAAH and NAAA. The results show that all of these compounds can 
inhibit FAAH and NAAA more or less. Compounds N9 and N16 show more high 
potential activities against FAAH and NAAA. They can inhibit FAAH by 98.35 % 
and84.90 % respectively , along with inhibiting NAAA by 80.82% and95.58 % at 100 
μM. Compounds N9 and N16 inhibit FAAH with IC50 values of 22.48 μM and 22.56 
μM, and inhibit NAAA with IC50 values of 18.55 μM and 10.68 μM on NAAA .  
④To further study the structure- activity relationship, we established two 
CoMFA models using reduction percentages of plasma TC and TG as biological 
activities, respectively. Of these two models, q2 (Cross-validated correlation 
coefficient) are 0.447 and 0.505 respectively; r2 (Non cross-validated correlation 
coefficient) are 0.974 and 0.968 respectively; SEE (Standard error of estimate) are 
3.372 % and 3.258 % respectively; F- test valide value are 166.197 and 136.554 
respectively. These parameters indicate that both of the two models are high in 
reliable. Based on the comparison between models and compounds structures, we 
obtain some important tructure- activity relationships which will be useful for the 
design of new hypolipidemic agents.     
On the basis of above work, we screened compounds N9 and N17 with superior 
activities of lowing hyperlipidemia and resistant hydrolysis enzyme, will be useful as 
new templates to design new and potent hypolipidemic agents.  
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5mg⁄Kg 的 OEA 能产生与腹腔注射 20mg⁄Kg PPAR-α合成激动剂 Wy-14643 相同
的降血脂效果[6]。该课题组一系列的实验证明，内源性 OEA 与同是 PPAR-α激动
剂的贝特类药物相比，降血脂效果更好，而且有明显的抑制食物摄取的作用。此
后，基于 OEA 结构的新化合物的设计和合成以及其降低体重活性的筛选成为研
究焦点。2006 年 Astarita 及其同事筛选到一种 OEA 类似物 KSD-5104 具有比 OEA
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图 1 OEA 结构 
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